Objectives: The aim of this study was to estimate cost/utility of infliximab for treatment of Chron's disease in Serbia and to calculate impact on national health budget if it is used according to evidence-based guidance for treatment of inflammatory bowel diseases. MethOds: Cost/utility of biological therapy of Chron's disease (infliximab in the first line, adalimumab for the patients unresponsive to infliximab) vs. azathioprine was estimated by Markov model written in Excel 2007. The model has 9 health states, with 30 two-month cycles. The model was populated from the perspective of Serbian society, taking into account both direct and indirect costs expressed in Serbian dinars (1 Euro = 120 RSD). Both costs and quality-adjusted life years (QALYs) were discounted at uniform rate of 3%. The model outputs were generated by Monte Carlo microsimulation, and further used for budget impact analysis. Conclusions of the model were challenged by probabilistic sensitivity analysis. Results: Biological therapy was cost effective in comparison with standard therapy, with ICER value of 2,091,348.98 ± 1,156,213.78 RSD per QALY gained (99% CI), and Neto monetary benefit of 90,183.84 ± 135,055.30 RSD (99% CI). About 62% of virtual patients generated by the model simulation were below the willingness of pay of 3 GDP per capita per QALY gained. Price of infliximab was the most influential variable on Neto monetary benefit in the sensitivity analysis. If infliximab and adalimumab are 100% reimbursed by Serbian health insurance fund for 3,927 patients with Chron's disease in Serbia who need biological therapy, additional annual burden on health budget in Serbia would be 180,248,853.03 ± 333,531,117.81 RSD (99% CI), or about 0.29% of total drug budget. cOnclusiOns: Biological therapy of Chron's disease in Serbia is cost/effective option, which would impose moderate burden on national health budget after full implementation according to recommendations of evidence-based international guidelines for treatment of inflammatory bowel diseases.
Objectives: Calprotectin is a calcium binding protein released by neutrophils associated with inflammation. A recent systematic review has confirmed the value of testing faecal calprotectin to help distinguish between organic (inflammatory bowel disease -IBD) and non-organic gastrointestinal disease (irritable bowel syndrome -IBS). National Institute of Clinical Excellence (NICE), UK guidelines were thus written to guide general practitioners (GPs) in excluding IBD and to achieve savings by reducing the number of referrals to secondary care. We aimed to determine the 12 month clinical outcomes of patients undergoing FC testing in primary and secondary care settings. MethOds: 495 FC test results between July 2012 to October 2013 were reviewed. Paediatric patients (< 16 years old) were excluded. Patients not referred to secondary care/tertiary care had their GPs contacted for further details. Long term clinical data was available in 275 patients; 208 normal, 41 intermediate and 26 raised FC results. Results: 40% of patients with a normal FC result were still referred to secondary gastroenterology care, with only 26% managed in primary care. 12 months post FC testing revealed 9% of normal FC results remained in secondary care, compared to 34% for intermediate and 73% for raised results. A new diagnosis of IBD was made in 1% of patients with normal FC results, 19% of intermediate and 38% of raised FC results. Conversely a new diagnosis of IBS (nonorganic) was made in 40% of normal FC, 27% of intermediate and 7.7% of raised results. cOnclusiOns: Despite a normal FC, this study suggests that 40% are still being referred to secondary care for investigation. This suggests that the cost saving intended by NICE may have been overestimated. The proportion of normal FC results which are managed in primary care could be improved with better GP education and more stringent pathways. Iakovlieva L, Gerasymova O, Mishchenko O, Bezditko N, Kyrychenko O, Kuznetsov I National University of Pharmacy, Kharkiv, Ukraine Objectives: The objective of this study is to determine the direct costs of the use of PPI for the treatment of erosive form (EF) and non-erosive form (NEF) of GERD in patients of working age in Ukraine. MethOds: Cost analysis for PPIs was conducted for a minimum course of treatment of GERD in one patient: NEF -4 weeks, EF -8 weeks. Daily doses of preparations were used in calculations: omeprazole, rabeprazole -20 mg; pantoprazole, esomeprazole -40 mg; lansoprazole -30 mg, (as recommended by the Ukrainian unified clinical protocol "Gastroesophageal Reflux Disease", 2013). When calculating the direct costs, the cost of PPIs was only taken into account. Prices of drugs were taken from the Morion information system "Drugs" (November 2014). The rate of hryvnia to dollar (USD) as of 28.11.14 was 14.96:1. To determine the range of costs for the use of PPIs, their trade names with the minimum and maximum costs of treatment of the disease in one patient were determined. Results: Ilaprazole achieved a better overall efficacy, because it is less impacted by CYP2C19 genotype subgroups. Compared with omeprazole, ilaprazole achieved an incremental cost effectiveness ratio of ¥132,056 per QALY gained which is less than the 3 times of China average GDP per capital (2014). A subgroup analysis suggests Ilaprazole is most cost-effective in the CYP2C19 subpopulation of Clinical efficacy and adverse event costs were not taken into consideration. The model also assumed reimbursement of infliximab-biosimilars in 2015 with low marketpenetration and conventional treatment almost steady throughout the three-year time horizon. Input data for estimated volumes were validated separately by two opinion leaders in gastroenterology (from a tertiary public and a private hospital), with vedolizumab experience through early-access programs. Any assumptions that showed discrepancies to expert opinion were converted to the average value of the two inputs. Values are in € 2015. Results: The increase in total costs from the introduction of vedolizumab and biosimilars to the Greek healthcare system, would be € 255,926, € 673,491 and € 814,924 for the three respective years post-entry (cumulative € 1,744,341). Average incremental per patient cost for the first year was found to be € 249 when vedolizumab and biosimilars received 21% and 11% of total UC biologic volumes respectively. Yearly total pharmaceutical UC expenditure ranged from € 2,735,702 to € 3,016,905 in the absence of vedolizumab and € 2,991,628 to € 3,831,829 when vedolizumab was available with estimated expenditure on biosimilar therapies not exceeding € 853,470 over three years. cOnclusiOns: Irrespective of the limitations due to lack of country-specific data, vedolizumab introduction is not expected to exert significant pressure on third party pharmaceutical UC expenditure.
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COst analysIs Of PrOtOn PumP InhIBItOrs In the treatment Of GastrOesOPhaGeal reflux DIsease In ukraIne
PGI5 veDOlIzumaB In CrOhn's DIsease; a BuDGet ImPaCt mODel fOr a nOvel DruG In a reCessIOn envIrOnment
Petrakis I, Koilakou S, Masouridou K, Kollia AM Takeda Hellas, Marousi Athens, Greece
Objectives: Crohn's disease (CD) exerts significant burden to IBD-patients and payers. The aim of this study was to estimate the budget impact of vedolizumab in moderate/severe CD, from the perspective of the Greek healthcare setting. MethOds: A Microsoft Excel-based budget impact model was adapted for a hypothetical cohort of IBD patients with moderate/severe CD within the total Greek population. The budget impact was calculated and presented as incremental drug-acquisition and administration costs, using input values obtained from National official databases, before and up to three years after the introduction of vedolizumab versus standard of care. Clinical efficacy and adverse event costs were not taken into consideration. The model also assumed reimbursement of infliximab-biosimilars in 2015 with low market-penetration and conventional treatment almost steady throughout the three-year time horizon. Input data for estimated volumes of vedolizumab and biosimilars were validated separately by two opinion leaders in gastroenterology from a tertiary public and a private hospital, with vedolizumab experience through early-access programs. Any assumptions that showed discrepancies to expert opinion were converted to the average value of the two inputs. Values are in € 2015. Results: The increase in total costs from the introduction of vedolizumab and infliximab-biosimilars to the Greek healthcare system, would be € 195,600, € 519,429 and € 788,147 for the three respective years post-entry (cumulative € 1,503,176). Average incremental per patient cost for the first year was found to be € 164 when vedolizumab and biosimilars received 10.9% and 3.3% of total CD biologic volumes respectively. Yearly total pharmaceutical CD expenditure ranged from € 5,024,036 to € 5,653,930 in the absence of vedolizumab and € 5,219,636 to € 6,442,077 when vedolizumab was available with estimated expenditure on biosimilar therapies not exceeding € 745,000 over three years. cOnclusiOns: Irrespective of the limitations due to lack of country-specific data, vedolizumab introduction is not expected to exert significant pressure on third party pharmaceutical CD expenditure. Objectives: The new combination therapy of paritaprevir, ombitasvir, dasabuvir, with/without ribavirin is highly tolerable, all-oral, interferon-free regimen for treatment of chronic hepatitis C virus (HCV) infection. The objective of present study was to evaluate the financial impact on the Croatian Health Insurance Fund (CHIF) budget following the introduction of the therapy for experienced HCV genotype 1 (GT1) patients. MethOds: The size of the eligible population for the new pharmaceutical combination was estimated by local demographics information, literature, and experts' opinion. Only direct costs of pharmaceuticals were taken into account. Budget impact calculations were based on healtheconomic outcomes of the new therapy in comparison to alternative interventions (standard dual-therapy and triple therapies that include boceprevir, telaprevir and simeprevir) for different patient subpopulations. Patient subpopulations were differentiated by response to previous treatment (relapse, partial response and null response), presence of cirrhosis and HCV GT1 subtype. Sensitivity analysis was performed in the form of alternative scenarios. Final parameters were estimated by Monte Carlo simulations. Results: The new combination therapy showed better efficiency, shorter duration and better tolerance in comparison to alternative interventions. For certain patient subpopulations, the new therapy is cheaper per achieved SVR in comparison to other therapies. The estimated number of patients eligible for the new combination therapy is 90-100 per year and the expected annual value of increased expenditures for CIHF budget is in between approximately 200,000 -900,000 € . cOnclusiOns: Although the impact on CHIF budget is significant, due to high efficiency and high tolerability, the new combination therapy for some patient subpopulations is cost-effective, that being the reason for its consideration as an alternative to standard therapies. Further, this economic evaluation could be the starting point for negotiations between pharmaceutical industry and insurance companies, as well as an introduction of specific contracts and some new technical solutions in those negotiations. impairment: 36.3%±24.8%. The most prevalent symptoms at baseline were abdominal pain (85.3%), constipation (7.5%) and bloating (76.5%). Mean IBS-QoL was 61.8±18.2 (scale: 0-100 [worst-best]). Mean EQ-5D was 58.4±20.2 (scale: 0-100 [worst-best]) and 85.3% and 50.9% of patients reported moderate-to-severe problems in pain/discomfort and anxiety/depression, respectively. Over the year, 78.4% patients consulted a primary care physician and 69.6% a gastroenterologist, 18.6% patients required emergency department visits/hospitalisation and 66.7% had a diagnostic test. 54.9% patients took prescription drugs for their IBS-C and 69.6% took non-prescription drugs. Mean (95%CI) annual direct costs per patient for Germany's national healthcare system: € 1,423 (621-2601); cost for the patient: € 539 (313-841); indirect cost: € 2,619 (1400-4131). The total annual cost: € 4,581 (2935-6569). cOnclusiOns: Moderate-tosevere IBS-C symptoms greatly impact German QoL and work productivity. Current management practices result in high direct and indirect costs. This results in significant cost to both the German national healthcare service and the patient, with the latter assuming one quarter of all direct medical costs. Objectives: Ulcerative colitis and Crohn´s disease, have a significant impact on health care budget. The aim of this study was to estimate costs of treatment and utilization of resources by patients with inflammatory bowel disease (IBD) in Serbia. MethOds: We performed a population-based, cost of illness study to identify direct, indirect and out of pocket costs of treatment of patients with IBD from societal perspective. Patients with Crohn´s disease (n = 59) and patients with ulcerative colitis (n = 53) completed semi-structured questionnaire with data about utilization of heath resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD), at one-year level. Results: Total direct costs per patient-year in group with Crohn´s disease were 1. 602, 97 Euro (192.614, 32 RSD) and total indirect costs per patient-year in group with Crohn's disease were 233,13 Euro (28.014,00 RSD). Total direct costs per patient-year in group with ulcerative colitis were estimated on 1.183,97 Euro (142.267,15 RSD) and total indirect costs per patient-year in group with ulcerative colitis were estimated on 178,39 Euro (21.436,00 RSD). The greatest part od direct costs were incurred by hospitalization (52.350,00 RSD per patient-year for Crohn's disease, and 47.895,00 RSD for ulcerative colitis), due to prolonged stay in a hospital (31 days per patient-year for Crohn's disease, and 34 days for ulcerative colitis). cOnclusiOns: Costs of IBD in Serbia are lower than in developed countries for two reasons: relatively expensive biologic therapy is under-utilized, and prices of health services largely used by the IBD patients are controlled by state on a very low level.
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PGI13
COsts Of InflamatOry BOWel DIsease (CrOhns DIsease anD ulCeratIve COlItIs) In serBIa
PGI14 real-WOrlD meDICal COsts Of antIvIral theraPy amOnG PatIents WIth ChrOnIC hCv InfeCtIOn anD aDvanCeD hePatIC fIBrOsIs
Maan R 1 , Zaim R 2 , van der Meer A 1 , Feld J 3 , Wedemeyer H 4 , Dufour J 5 , Lammert F 6 , Manns M 4 , Zeuzem S 7 , Hansen B 1 , Janssen H 3 , Veldt B 1 , de Knegt R 1 , Uyl-de Groot C 2 1 Erasmus MC University Medical Center, Rotterdam, The Netherlands, 2 Erasmus University, Rotterdam, The Netherlands, 3 Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada, 4 Medical School Hannover, Hannover, Germany, 5 University of Bern, Bern, Switzerland, 6 Saarland University Medical Center, Homburg, Germany, Frankfurt, Germany Objectives: The aims of our multicenter study were to quantify direct medical costs during interferon (IFN)-based antiviral treatment and per sustained virological response (SVR) among patients with chronic hepatitis C-virus (HCV) infection and advanced hepatic fibrosis in the Netherlands, Germany, Switzerland and Canada. MethOds: Direct medical costs were quantified during IFN-based treatments received by all consecutive patients (N= 455) with chronic HCV infection and biopsy-proven bridging fibrosis or cirrhosis (Ishak scores 4-6). The components of care from initiation of therapy were quantified by three distinct categories: treatment, safety-monitoring and complications. Total medical costs attributable to each cost component were calculated and expressed in 2013 Euros. Sensitivity analyses were performed to explore the influence of components of care and the SVR rate on medical costs. Results: In total, 672 IFN-based treatments, administered to 455 patients, were included in the analysis. At time of inclusion, median age was 48 years (IQR 43-56), 317 (70%) patients were male, and 346 (76%) presented with cirrhosis. Platelet counts were available for 432 (95%) patients, of whom 226 (52%) had thrombocytopenia. Total mean medical costs per treatment were € 14,559 (95% CI, € 13,323-€ 15,836). Among patients with a normal platelet count and thrombocytopenia, mean costs were € 12,419 (95%CI, € 10,974-€ 13,937) and € 14,416 (95%CI, € 12,503-€ 16,598), respectively. The costs per SVR were € 26,105 (95%CI, € 23,068-€ 29,296) for patients with normal platelet counts and € 50,907 (95%CI, € 44,151-€ 59,612) for patients with thrombocytopenia. In patients with severe thrombocytopenia (platelet count below 100*109/L) the costs per SVR were € 74,961 (95%CI, € 55,463-€ 103,541). The corresponding SVR rates were 48%, 28% and 18%, respectively. Sensitivity analyses confirmed the robustness of our results. cOnclusiOns: Real-world medical costs did not differ significantly among patients with or without thrombocytopenia. However, the SVR rate was lower among patients with severe thrombocytopenia, in whom the medical costs per SVR with IFN-based therapy were substantial.
PGI15 eCOnOmIC BurDen In stuDIes PuBlIsheD In 2014: What tyPe Of GastrOIntestInal DIsOrDers, InterventIOns anD OutCOmes have Been mOst COmmOnly assesseD?
Martin A Crystallise Ltd., London, UK heterogeneous extensive metabolizer, which had the incremental cost effectiveness ratio of ¥57,810 per QALY gained. Probabilistic sensitivity analysis suggests that the results are robust with 97% probability that ilaprozole is consider cost effective when 3 times China average GDP per capital threshold is used. cOnclusiOns: The cost-effectiveness analysis results demonstrated that ilaprazole would be considered cost-effective compared with omeprazole to treat newly diagnosed duodenal ulcer patient in China. When treating the duodenal ulcer patients who are CYP2C19 subpopulation of heterogeneous extensive metabolizer, ilaprazole is highly costeffective, compared with omeprazole.
PGI10 strenGths anD Weaknesses Of Current ClInICal anD eCOnOmIC evIDenCe fOr the COmParIsOn Of laParOsCOPIC versus OPen rePaIr Of InCIsIOnal hernIa
Hargreaves JA Covidien (UK) Commercial Ltd, now part of Medtronic, Whiteley, Fareham, UK Objectives: Incisional hernias are common following abdominal surgery and place a significant burden on patients and healthcare resources. There are two main approaches to mesh-based surgical repair of an incisional hernia: open surgery and laparoscopy. To date, however, no consensus has been reached as to which approach is preferred. The aim of this study was to review the strengths and weaknesses of current clinical and economic evidence comparing laparoscopic with open repair of incisional hernias. MethOds: Studies investigating clinical and economic outcomes of laparoscopic and open incisional hernia repair published between 2003-2014 were identified. Due to the paucity of available data, evidence is supplemented using findings from large database studies. Other types of study were considered for specific outcomes only when no other evidence was available. Results: Overall, there is a relatively large body of consistent evidence to conclude that laparoscopic repair of incisional hernia is at least equal to open repair in terms of mortality, short-to medium-term recurrence, complications, pain and quality of life, with a possibly longer operative time. In addition, laparoscopic repair of incisional hernia has consistently been shown to be associated with fewer infections and a shorter hospital stay than open repair. Although economic data are limited, there is consistent evidence from studies that compared the costs for both laparoscopic and open repair of incisional/ventral hernia to suggest that the higher operational costs associated with laparoscopic repair, which have been attributed, variously, to a longer operative time, a need for more expensive mesh or greater supply costs in several studies appear to be offset by the shorter hospital stay associated with the procedure. cOnclusiOns: There is consistent evidence to suggest that laparoscopic repair is associated with lower rates of infection and shorter hospital stays (and consequently lower overall costs) than open surgery. Objectives: To perform comparative pharmacoeconomic study of the application of IV generation of pancreatin drugs in patients with pancreatic exocrine insufficiency on the hospital stage of medical care. MethOds: A pharmacoeconomic model of administration of IV generation of pancreatin drugs (creon and ermital) in adult patients (100 persons in compared groups) during replacement therapy of pancreatic functional insufficiency was developed. Dosage of the drugs was at least 100 000 units of lipolytic activity per 24 h. Time horizon was 21 days. Measures of clinical efficiency of the applied therapy were the number of patients, who would reach clinical response according to "pain relief" and "diarrhea relief" parameters. Results: In the modeled conditions, costs of drug therapy per patient were within the range of 962.78 -1,869.56 RUB in the group of creon and 736.12 -1,237.20 for ermital, depending on the dose. CER values were: pain relief in the range of 1,046.5 -2,032.13 in creon group, and 836.50 -1,405.90 in ermital group; diarrhea relief was in the range of 927.38 -1,927.38 in creon group and 783.10 -1,316.17 in ermital group. cOnclusiOns: The conducted clinical and economical research demonstrated pharmacoeconomic advantages of ermital administration. It should be noted that the results of this work were significantly influenced by the applied dosages of medications, which were one of the key factors of economical substantiation of use of the considered medical technologies.
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PGI12 eCOnOmIC BurDen anD QualIty Of lIfe Of mODerate-tO-severe IrrItaBle BOWel synDrOme WIth COnstIPatIOn (IBs-C) In Germany: results frOm the IBIs-C stuDy
Layer P 1 , Andresen V 1 , Diemert S 2 , Mackinnon J 3 , Bertsch J 3 , Fortea J 2 , Tack J 4 1 Israelitic Hospital, Hamburg, Germany, 2 Almirall S.A, Barcelona, Spain, 3 TFS Develop S.L, Barcelona, Spain, 4 University Hospital Gasthuisberg, Leuven, Belgium Objectives: To assess the socio-economic burden of moderate-to-severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and UK). Here we present the economic and quality of life (QoL) results from Germany. MethOds: Observational, retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome-III criteria) and with moderate-to-severe disease at inclusion (IBS-Symptom Severity Scale [IBS-SSS] score ≥ 175). The primary objective was to determine annual direct and indirect costs. Secondary objectives included assessing QoL at baseline: IBS-QoL and EuroQoL-5D (EQ-5D) questionnaires. Work productivity was assessed using the Work Productivity and Activity Impairment:IBS-C questionnaire (WPAI:IBS-C). Results: 102 patients were included from Germany: mean (±SD) age 47.6±18.1 years, 83.3% female, 43.1% severe (IBS-SSS). In the week prior to baseline, mean presenteeism (WPAI:IBS-C) was: 35.6%±28.2% of time; absenteeism: 14.7%±28.2%; work productivity loss: 44.1%±32.7%; daily activity
